After decades of debate within the IP bar and the Federal Circuit U.S. Court of Appeals, a divided en banc panel on Monday established the standard for evaluating so-called “patent-by-process” claims, which involve patents that are defined, at least in part, by the process used to make the product.
The case involved Abbott Laboratories’ patent for the drug Omnicef, an antibiotic that is often used to treat children’s ear infections. After the FDA approved Lupin Limited’s generic version of the drug, cefdinir, Lupin sought a declaratory judgment in the Eastern District of Virginia that it did not infringe, arguing that it used a different process to make its drug. The court ruled for Lupin and Abbott appealed. The case was later combined with a similar dispute between Abbott, Sandoz and Teva Pharmaceuticals that originated in the Northern District of Illinois.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
